ReviewCurrent allergy and asthma reports2020
Role of Environmental Adjuvants in Asthma Development.
Review in Current allergy and asthma reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 10 citations in OpenAlex.
- Indoor allergens and endotoxins in relation to cockroach infestations in low-income urban homes.The journal of allergy and clinical immunology. Global · 2026Article
- AI-Driven Data Analysis for Asthma Risk Prediction.Healthcare (Basel, Switzerland) · 2025Article
- Article
- Emerging Insights into the Impact of Air Pollution on Immune-Mediated Asthma Pathogenesis.Current allergy and asthma reports · 2022Review
- Neuropilin-2 regulates airway inflammation in a neutrophilic asthma model.Immunity, inflammation and disease · 2022Article
- A neutrophil/TGF-β axis limits the pathogenicity of allergen-specific CD4+ T cells.JCI insight · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
purpose of reviewThis review summarizes recent progress in our understanding how environmental adjuvants promote the development of asthma. RECENT
findingsAsthma is a heterogeneous set of lung pathologies with overlapping features. Human studies and animal models suggest that exposure to different environmental adjuvants activate distinct immune pathways, which in turn give rise to distinct forms, or endotypes, of allergic asthma. Depending on their concentrations, inhaled TLR ligands can activate either type 2 inflammation, or Th17 differentiation, along with regulatory responses that function to attenuate inflammation. By contrast, a different category of environmental adjuvants, proteases, activate distinct immune pathways and prime predominantly type 2 immune responses. Asthma is not a single disease, but rather a group of pathologies with overlapping features. Different endotypes of asthma likely arise from perturbations of distinct immunologic pathways during allergic sensitization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.